A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2013
At a glance
- Drugs Dacomitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 25 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jun 2012 Planned End Date changed from 1 Feb 2013 to 1 Aug 2012 as reported by ClinicalTrials.gov.